Psychedelic Experiences Clinical Trial
— SERPNTSOfficial title:
Entheogen Resurgence - Surveying Entheogen Retreat Participants in Naturalistic Settings
Verified date | January 2022 |
Source | Vireo Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
For the purpose of this anonymous, observational pilot survey, the investigators will define "entheogens" as substances, generally derived from plants, that are ingested in order to impact one's consciousness for therapeutic, religious, or spiritual purposes. This survey will focus on the naturalistic use of entheogens and other substances including kambo, ayahuasca, hapé, bufo, and sananga typically used in specific cultural and spiritual contexts for healing. There are substantial limitations to what the healthcare community knows about the intentions, motivations, experiences, health behaviors, and demographics of people who decide to participate in entheogen therapy centers or retreats and their willingness to participate in future research studies. The primary goal of this observational pilot survey is to collect self-reported, anonymous data from people who have opted to participate in entheogen therapy centers and retreats during the last five (5) years on the topics of their initial intentions, motivations, experiences, demographics, and willingness to participate in future entheogen research. With the support of established therapy and retreat centers, the research team will aim to collect 100 survey responses from unique, unidentified individuals who have participated in some form of entheogen therapy or treatment during the last five (5) years. Those who choose to fill out the survey will be at least 18 years of age, fluent in English, and self-reporting participation in therapy or a retreat which utilized entheogens in a naturalistic setting in the past five (5) years.
Status | Completed |
Enrollment | 102 |
Est. completion date | January 12, 2022 |
Est. primary completion date | January 12, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - >18 years old - Fluent in English - Self-reported participation in therapy or a retreat in a naturalistic setting that incorporated the use of entheogens in the past five (5) years Exclusion Criteria: - Inability to provide informed consent - Inability to complete the online questionnaire - No self-reported participation in therapy or a retreat in a naturalistic setting that incorporated the use of entheogens in the past five (5) years - Self-reported participation in therapy or a retreat in naturalistic setting that incorporated the use of entheogens greater than five (5) years ago |
Country | Name | City | State |
---|---|---|---|
United States | Vireo Health of New York | Queens | New York |
Lead Sponsor | Collaborator |
---|---|
Vireo Health |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Entheogen Use in Naturalistic Retreat & Therapeutic Settings | The primary outcome will be self-reported experiences related to entheogen use in naturalistic retreat and therapeutic settings. | Entheogen use will have occured within the last 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05468047 -
Ketamine Therapy Experiential Education Study
|
Early Phase 1 | |
Enrolling by invitation |
NCT05592379 -
Consciousness, Psilocybin, and Well-Being
|
Phase 1 | |
Completed |
NCT04842045 -
Pilot RECAP Study in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04965740 -
Exploring Medically Perceived Benefits, Use and Interest in Psychedelics and Cannabinoids
|
||
Not yet recruiting |
NCT06450210 -
Safety for Home Administration of Microdose Psilocybin Use
|
Phase 1 | |
Recruiting |
NCT05698511 -
Neural and Physiological Correlates of Psychedelic Sub-states
|
Phase 1 | |
Withdrawn |
NCT05252598 -
Mood and Cognitive Effects of Psilocybin in Healthy Participants
|
Early Phase 1 | |
Terminated |
NCT04424225 -
Visual Surround Suppression and Perceptual Expectation Under Psilocybin
|
Phase 1 | |
Not yet recruiting |
NCT05866471 -
Pairing Psilocybin With Transcutaneous Auricular Vagus Nerve Stimulation
|
Phase 1 |